Protara Initiates Phase 3 Trial for IV Choline Chloride to Address Choline Deficiency in Long-Term Parenteral Support Patients.
ByAinvest
Wednesday, Jan 7, 2026 9:51 am ET1min read
TARA--
Protara Therapeutics has dosed the first patient in its Phase 3 THRIVE-3 trial for IV Choline Chloride to treat choline deficiency in patients on long-term parenteral support. The trial aims to establish IV choline as the first FDA-approved therapy for this underserved population. Interim analysis is expected in H2 2026. The stock has traded between $2.77 and $7.82 over the past year and is currently at $5.46, up 6.42%.
Stay ahead of the market.
Get curated U.S. market news, insights and key dates delivered to your inbox.
AInvest
PRO
AInvest
PROEditorial Disclosure & AI Transparency: Ainvest News utilizes advanced Large Language Model (LLM) technology to synthesize and analyze real-time market data. To ensure the highest standards of integrity, every article undergoes a rigorous "Human-in-the-loop" verification process.
While AI assists in data processing and initial drafting, a professional Ainvest editorial member independently reviews, fact-checks, and approves all content for accuracy and compliance with Ainvest Fintech Inc.’s editorial standards. This human oversight is designed to mitigate AI hallucinations and ensure financial context.
Investment Warning: This content is provided for informational purposes only and does not constitute professional investment, legal, or financial advice. Markets involve inherent risks. Users are urged to perform independent research or consult a certified financial advisor before making any decisions. Ainvest Fintech Inc. disclaims all liability for actions taken based on this information. Found an error?Report an Issue
Comments
No comments yet